Stock Events

Transmedics 

$152.35
583
+$2.85+1.91% Friday 20:00

統計

當日最高
152.47
當日最低
149.17
52週最高
154.14
52週最低
36.42
成交量
364,941
平均成交量
705,216
市值
5.02B
市盈率
-494.96
股息收益率
-
股息
-

收益

30Apr確認
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.78
-0.4
-0.03
0.35
預期每股收益
-0.05
實際每股收益
0.35

人們還關注

此列表基於在 Stock Events 上關注 TMDX 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

分析師評級

130$平均價格目標
最高估價為 $175。
來自過去 6 個月內的 7 個評級。這不是投資建議。
買入
86%
持有
14%
賣出
0%

關於

Medical Specialties
Health Technology
Manufacturing
Surgical and Medical Instrument Manufacturing
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Show more...
首席執行官
Waleed H. Hassanein
員工
584
國家
US
ISIN
US89377M1099
WKN
000A2PH5P

上市公司